Sunday, February 18, 2018

Eye Drops May Treat Macular Degeneration in Future

Age Related Macular Degeneration (AMD) can cause people to lose central vision and is a leading cause of vision loss in seniors. The prompt treatment of “Wet” Macular Degeneration is very helpful in preventing catastrophic vision loss for most patients. The “Wet” form of AMD is currently treated by repeated injections into the eye of drugs called Vascular Endothelial Growth Factor (VEGF) inhibitors-that stop, reverse and prevent new blood vessel growth. The most common VEGF inhibitors include Lucentis®, Eylea® and Avastin® and often require monthly injections to be effective. Researchers from the University of Birmingham (UK) Institute Inflammation and Aging reporting in the journal Investigative Ophthalmology & Visual Science have developed a method of delivering the AMD treatment drugs via an eye drop rather than by injection. The eye drop uses a molecule called a cell–penetrating peptide (CPP) to deliver the drug to the relevant part of the eye and hold future promise for treating Age Relater Macular Degeneration (AMD) with eye drops rather than injections.

If you or someone you know has a family history of Age Related Macular Degeneration (AMD) and is over 50 years of age or is a senior who has not had regular eye exams, please schedule and eye exam to help us help you avoid vision loss. Please call Alabama Eye & Cataract Center in Birmingham at 205-930-0930, visit Alabama Eye & Cataract Center, Google+ or